Please login to the form below

Not currently logged in
Email:
Password:

Tylenol recall prompts investigation

A US House Committee is looking at Johnson & Johnson following the recall of several OTC paediatric children's medicines, including Tylenol

A US House Committee is looking at Johnson & Johnson after the company announced a recall of several over-the-counter (OTC) paediatric children's medicines manufactured in the US, including Tylenol (paracetamol).

US lawmakers requested information on Thursday from regulators about Johnson & Johnson's recall of Tylenol and other over-the-counter paediatric medicines, saying the company's repeated recalls "point to a major problem with production".

In a US Food and Drug Administration (FDA) report issued on Tuesday May 4, inspectors said they found thick dust, grime and contaminated ingredients at the plant that produces children's Tylenol and dozens of other products recalled last week.

The McNeil Consumer Healthcare plant in Fort Washington, which manufactured the recalled drugs, has been on a stepped up inspection schedule by federal regulators since 2008. This is the third voluntary recall of products within the Tylenol porfolio this year.

Information on McNeil's website for Tylenol states that: "Some of the products included in the recall may contain a higher concentration of active ingredient than is specified; others may contain inactive ingredients that may not meet internal testing requirements; and others may contain tiny particles. While the potential for serious medical events is remote, the company advises consumers who have purchased these recalled products to discontinue use."

10th May 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics